Survivin 1, also known as BIRC5, is an inhibitor of apoptosis and is present during normal fetal development, but disappears in most differentiated adult tissues.
The protein is highly expressed in most cancer types and shows an enhanced expression in most human cancers, including melanoma.
The overexpression of Survivin 1 in malignant tissues, as well as the beneficial effect on tumor growth, makes this protein an attractive candidate for immunotherapeutic strategies.
The in vitro
stimulation of Survivin 1-specific CD4+
T cells with MACS GMP PepTivator Survivin 1 results in production of the effector cytokine IFN-gamma. The presence of IFN-gamma on the cell surface then permits the enrichment of Survivin 1-specific effector/memory T cells with the use of the CliniMACS Cytokine Capture System (IFN-gamma).
Due to the strong expression of Survivin 1 in various cancer types, the adoptive transfer of Survivin 1-specific T cells or the vaccination with Survivin 1-pulsed dendritic cells represent a promising tool for immunotherapeutic approaches.